| __timestamp | Dynavax Technologies Corporation | Galapagos NV |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 9079000 |
| Thursday, January 1, 2015 | 22180000 | 20309000 |
| Friday, January 1, 2016 | 37257000 | 16945000 |
| Sunday, January 1, 2017 | 27367000 | 20559000 |
| Monday, January 1, 2018 | 64770000 | 29641000 |
| Tuesday, January 1, 2019 | 74986000 | 88258000 |
| Wednesday, January 1, 2020 | 79256000 | 162170000 |
| Friday, January 1, 2021 | 100156000 | 167218000 |
| Saturday, January 1, 2022 | 131408000 | 239528000 |
| Sunday, January 1, 2023 | 152946000 | 94252000 |
Igniting the spark of knowledge
In the ever-evolving biotech industry, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Dynavax Technologies Corporation and Galapagos NV from 2014 to 2023. Over this period, Dynavax's SG&A expenses surged by approximately 760%, peaking in 2023, while Galapagos NV experienced a more modest increase of around 940% until 2022, before a notable decline in 2023.
The year 2020 marked a pivotal point for both companies, with Galapagos NV's expenses nearly doubling compared to the previous year, reflecting strategic investments in research and development. Meanwhile, Dynavax's expenses steadily climbed, highlighting its commitment to expanding its market presence. This comparative analysis underscores the dynamic nature of financial strategies in the biotech sector, offering valuable insights for investors and industry enthusiasts alike.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Sanofi and Dynavax Technologies Corporation
argenx SE and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Galapagos NV
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
Comparing SG&A Expenses: Cytokinetics, Incorporated vs Galapagos NV Trends and Insights
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Opthea Limited and Galapagos NV
Selling, General, and Administrative Costs: Verona Pharma plc vs Galapagos NV
SG&A Efficiency Analysis: Comparing Vericel Corporation and Galapagos NV
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation